Group addressed what we believe are inaccurate and misleading claims made in a short-seller report issued by Scorpion ...

If you purchased TransMedics securities you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement. The Rosen Law Firm is preparing a ...

TransMedics Group, Inc. TMDX recently issued a statement refuting the claims made in a report by short-seller Scorpion Capital on Jan. 10, 2025, stating them as inaccurate and misleading.

TransMedics is facing allegations of fraud, organ trafficking, and unethical practices that have triggered shareholder ...

Shares of organ transplant innovator TransMedics Group ( TMDX -1.41%) fell 15.7% through Thursday trading, according to data from S&P Global Market Intelligence. TransMedics was the target of an ...

Scorpion alleged the company operates a "mafia-style" scheme involving off-label device misuse and customer attrition, as it set TransMedics target price of $0. “Investors sense something is ...

("TransMedics") (Nasdaq: TMDX), a medical technology company that is transforming organ transplant therapy for patients with end-stage lung, heart and liver failure, today addressed what we believe ...

Dey, Aiyesha, Jonas Heese, Suraj Srinivasan, and Annelena Lobb. "Ginkgo Bioworks vs. Scorpion Capital: The Debate Over Related-Party Revenues." Harvard Business School Case 123-037, October 2022.

Scorpion Capital accuses TransMedics of fraudulent practices, kickbacks, and racketeering, setting a price target of $0.00. TransMedics denies the claims, stating the allegations aim to manipulate ...

NEW YORK, NY / ACCESS Newswire / January 22, 2025 / Pomerantz LLP is investigating claims on behalf of investors of TransMedics Group, Inc. ("TransMedics" or the "Company") (NASDAQ:TMDX). Such ...